These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37860779)

  • 61. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
    Robles G; Sauermilch D; Gandhi M; Starks TJ
    AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
    Velloza J; Donnell D; Hosek S; Anderson PL; Chirenje ZM; Mgodi N; Bekker LG; Marzinke MA; Delany-Moretlwe S; Celum C
    Lancet HIV; 2022 Oct; 9(10):e680-e689. PubMed ID: 36087612
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
    Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
    PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
    Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
    J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
    Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection.
    Stalter RM; Pintye J; Mugwanya KK
    Expert Opin Drug Saf; 2021 Nov; 20(11):1367-1373. PubMed ID: 33998936
    [No Abstract]   [Full Text] [Related]  

  • 67. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.
    Pornpaisalsakul K; Songtaweesin WN; Tepmongkol S; Wongharn P; Kawichai S; Suponsilchai V; Anugulruengkitt S; Puthanakit T;
    J Int AIDS Soc; 2020 Oct; 23(10):e25624. PubMed ID: 33040465
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Preexposure prophylaxis for HIV infection among African women.
    Van Damme L; Corneli A; Ahmed K; Agot K; Lombaard J; Kapiga S; Malahleha M; Owino F; Manongi R; Onyango J; Temu L; Monedi MC; Mak'Oketch P; Makanda M; Reblin I; Makatu SE; Saylor L; Kiernan H; Kirkendale S; Wong C; Grant R; Kashuba A; Nanda K; Mandala J; Fransen K; Deese J; Crucitti T; Mastro TD; Taylor D;
    N Engl J Med; 2012 Aug; 367(5):411-22. PubMed ID: 22784040
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
    Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
    Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?
    Kojima N; Klausner JD
    Open Forum Infect Dis; 2016 Jan; 3(1):ofv221. PubMed ID: 26949714
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.
    Matthews LT; Heffron R; Mugo NR; Cohen CR; Hendrix CW; Celum C; Bangsberg DR; Baeten JM;
    J Acquir Immune Defic Syndr; 2014 Sep; 67(1):91-7. PubMed ID: 25118795
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Low prevalence of hepatitis B virus infection in HIV-uninfected pregnant women in Cape Town, South Africa: implications for oral pre-exposure prophylaxis roll out.
    Joseph Davey D; Hsiao NY; Wendy Spearman C; Sonderup M; Hu NC; Mashele N; Mvududu R; Myer L
    BMC Infect Dis; 2022 Sep; 22(1):719. PubMed ID: 36050648
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
    Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
    PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.
    Mugwanya KK; John-Stewart G; Baeten J
    Expert Opin Drug Saf; 2017 Jul; 16(7):867-871. PubMed ID: 28571500
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study.
    Koss CA; Charlebois ED; Ayieko J; Kwarisiima D; Kabami J; Balzer LB; Atukunda M; Mwangwa F; Peng J; Mwinike Y; Owaraganise A; Chamie G; Jain V; Sang N; Olilo W; Brown LB; Marquez C; Zhang K; Ruel TD; Camlin CS; Rooney JF; Black D; Clark TD; Gandhi M; Cohen CR; Bukusi EA; Petersen ML; Kamya MR; Havlir DV;
    Lancet HIV; 2020 Apr; 7(4):e249-e261. PubMed ID: 32087152
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
    Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW
    J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence.
    Haberer JE; Kidoguchi L; Heffron R; Mugo N; Bukusi E; Katabira E; Asiimwe S; Thomas KK; Celum C; Baeten JM
    J Int AIDS Soc; 2017 Jul; 20(1):21842. PubMed ID: 28741331
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study.
    Mboup A; Béhanzin L; Guédou FA; Geraldo N; Goma-Matsétsé E; Giguère K; Aza-Gnandji M; Kessou L; Diallo M; Kêkê RK; Bachabi M; Dramane K; Geidelberg L; Cianci F; Lafrance C; Affolabi D; Diabaté S; Gagnon MP; Zannou DM; Gangbo F; Boily MC; Vickerman P; Alary M
    J Int AIDS Soc; 2018 Nov; 21(11):e25208. PubMed ID: 31291057
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting.
    Montgomery MC; Oldenburg CE; Nunn AS; Mena L; Anderson P; Liegler T; Mayer KH; Patel R; Almonte A; Chan PA
    PLoS One; 2016; 11(6):e0157742. PubMed ID: 27333000
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.